Drugs / EnvPro
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00623753 | May 2007 → Jan 2008 | HIV infectious disease | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT00076947 | Aug 2003 → ? | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EnvPro | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00623753 ↗ |
| Modality | Vaccine | “EnvPro is a recombinant, purified envelope protein vaccine with an aluminum hydroxide (alum) adjuvant.” NCT00076947 ↗ |
| Route | Intramuscular | “All participants in this study will receive vaccine injections in the upper arm muscle.” NCT00076947 ↗ |